Press coverage about Iovance Biotherapeutics (NASDAQ:IOVA) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Iovance Biotherapeutics earned a daily sentiment score of 0.08 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.4371500821728 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Shares of Iovance Biotherapeutics (IOVA) opened at $8.00 on Thursday. The company has a market cap of $599.22, a P/E ratio of -6.15 and a beta of 4.59. Iovance Biotherapeutics has a 12 month low of $4.45 and a 12 month high of $9.54.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.01). analysts predict that Iovance Biotherapeutics will post -1.37 EPS for the current year.

IOVA has been the subject of several research reports. HC Wainwright set a $16.00 price objective on Iovance Biotherapeutics and gave the stock a “buy” rating in a research report on Monday, October 30th. BidaskClub downgraded Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 22nd. Oppenheimer set a $13.00 price objective on Iovance Biotherapeutics and gave the stock a “buy” rating in a research report on Thursday, October 12th. Jefferies Group restated a “buy” rating on shares of Iovance Biotherapeutics in a research report on Sunday, October 29th. Finally, FBR & Co restated a “buy” rating and set a $17.50 price objective on shares of Iovance Biotherapeutics in a research report on Wednesday, October 25th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $14.53.

WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Iovance Biotherapeutics (IOVA) Stock Price” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Insider Buying and Selling by Quarter for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with's FREE daily email newsletter.